Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2019	Dec. 31, 2018
Current assets:
Cash and cash equivalents	$ 8,136	$ 16,660
Restricted cash	4	4
Prepaid expenses and other current assets	386	461
Total current assets	8,526	17,125
Property, equipment and leasehold improvements, net	70	100
Restricted cash - non current	110	110
Operating lease right-of-use assets	1,278
Prepaid clinical trial expenses	1,130	996
Other assets	30	46
Total assets	11,144	18,377
Current liabilities:
Accounts payable	821	815
Loan payable, current portion		100
Operating lease liabilities	286
Accrued expenses	1,020	1,290
Total current liabilities	2,127	2,205
Other liabilities	63	61
Operating lease liabilities - non current	1,097
Total liabilities	3,287	2,266
Commitments and contingencies (Note 5)
Stockholders’ equity:
Common stock, $0.00001 par value, authorized 25,000,000 shares; 9,519,570 shares issued and outstanding, including 206,500 shares of unvested restricted stock, at September 30, 2019; 9,309,255 shares issued and outstanding at December 31, 2018	1	1
Additional paid-in capital	223,644	223,440
Accumulated deficit	(215,788)	(207,330)
Total stockholders’ equity	7,857	16,111
Total liabilities and stockholders’ equity	$ 11,144	$ 18,377